Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial f…
Biotechnology
US, Redwood City [HQ]
Document Reader
Link Index · Filing Reader · 10K/10QThis analysis tool lets you read the documents of Revolution Medicines, Inc.
DEF 14-A Proxies
10-Ks
10-Qs
LDA 1/2s
Click To Read:
DEF 14-A Proxies
Not a single DEF 14-A proxy doc.
10-K Filings
Not a single 10-K doc.
10-Q Filings
LDA 1/2 Filings [Lobbying]
Not a single LDA doc.